Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted EBITDA Margin of 17.13% for Q1 2026, down 7.35% sequentially from 18.48% in Q4 2025, and up 3470.0% YoY from 0.48% in Q1 2025.
Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported EBITDA Margin for 9 years, with the latest figure at 17.13% in Q1 2026.
- Quarterly EBITDA Margin rose 3470.0% year-over-year to 17.13% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.9% (up 2915.0% YoY) and the FY2025 annual result came in at 9.19%, up 3222.0% from the prior year.
- EBITDA Margin retreated to 17.13% in Q1 2026 per ADPT's latest filing, from 18.48% in the prior quarter.
- Over five years, EBITDA Margin peaked at 18.48% in Q4 2025 and troughed at 322.32% in Q2 2023.
- A 5-year average of 62.31% and a median of 26.14% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 20207 bps in 2023, then surged 29619 bps in 2024.
- Over 5 years, EBITDA Margin stood at 70.99% in 2022, then surged by 109 bps to 6.34% in 2023, then sank by 318 bps to 13.81% in 2024, then soared by 234 bps to 18.48% in 2025, then decreased by 7 bps to 17.13% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 17.13%, 18.48%, and 7.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | 17.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.13% |
| Dec 31, 2025 | 18.48% |
| Sep 30, 2025 | 7.41% |
| Jun 30, 2025 | -10.31% |
| Mar 31, 2025 | -17.58% |
| Dec 31, 2024 | -13.81% |
| Sep 30, 2024 | -24.40% |
| Jun 30, 2024 | -26.14% |
| Mar 31, 2024 | -67.30% |
| Dec 31, 2023 | 6.34% |
| Sep 30, 2023 | -78.67% |
| Jun 30, 2023 | -322.32% |
| Mar 31, 2023 | -98.54% |
| Dec 31, 2022 | -70.99% |
| Sep 30, 2022 | -94.98% |
| Jun 30, 2022 | -120.25% |
| Mar 31, 2022 | -163.30% |
| Dec 31, 2021 | -162.39% |
| Sep 30, 2021 | -142.71% |
| Jun 30, 2021 | -129.24% |